SELP
P-selectin
As of the edition of 20 October 2026, SELP (P-selectin, UniProt P16109) has 4 drugs tested at it and 6 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16109
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Blood and lymph; Inherited and neonatal; Urinary and reproductive; Heart and blood vessels; Infections; Lungs and airways; Pregnancy and women's health; Eye
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Crizanlizumab | Marketed | Phase 4 | Ends 2031 |
| Rivipansel | Stopped | Phase 3 | none listed |
| Inclacumab | Stopped | Phase 3 | none listed |
| PSI-697 | Went quiet | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 6 |
The other 3 companies at SELP
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at SELP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.